The estimated Net Worth of Thomas Woiwode is at least $37.7 Million dollars as of 30 December 2020. Thomas Woiwode owns over 1,347,709 units of Adverum Biotechnologies Inc stock worth over $9,474,394 and over the last 9 years he sold ADVM stock worth over $27,775,688. In addition, he makes $468,103 as Independent Director at Adverum Biotechnologies Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Thomas Woiwode ADVM stock SEC Form 4 insiders trading
Thomas has made over 15 trades of the Adverum Biotechnologies Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 1,347,709 units of ADVM stock worth $5,000,000 on 30 December 2020.
The largest trade he's ever made was buying 1,347,709 units of Adverum Biotechnologies Inc stock on 30 December 2020 worth over $5,000,000. On average, Thomas trades about 57,717 units every 34 days since 2016. As of 30 December 2020 he still owns at least 1,347,709 units of Adverum Biotechnologies Inc stock.
You can see the complete history of Thomas Woiwode stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Thomas Woiwode biography
Dr. Thomas Woiwode Ph.D. serves as Independent Director of the Company. Dr. Woiwode has been with Versant Ventures, a venture capital firm, since 2002 in various capacities, serving as a Venture Partner since 2011 and a managing director since 2014. He has served in a number of operating roles over this time, most recently as the chief operating officer of Okairos AG, a biopharmaceutical company, from April 2011 until May 2013, when Okairos was sold to GlaxoSmithKline plc. Prior to Okairos, Dr. Woiwode co-founded EuroVentures, a wholly owned biotech incubator within Versant Ventures, and in this role, served as the founding chief business officer for three biotech companies created within Versant. Dr. Woiwode was a research scientist at XenoPort, Inc., a biotechnology company, before joining Versant. Dr. Woiwode serves on the board of directors of several private companies and two other publicly traded companies, CRISPR Therapeutics AG and Gritstone Oncology, Inc. and previously served on the board of directors of Audentes Therapeutics, Inc., a gene therapy company. He received a B.A. in English and a B.S. in Chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from Stanford University. Dr. Woiwode has been chosen to serve on our Board due to his educational background, his experience as a board member and senior executive of biotechnology and pharmaceutical companies, and his experience as an investor in new life sciences companies.
What is the salary of Thomas Woiwode?
As the Independent Director of Adverum Biotechnologies Inc, the total compensation of Thomas Woiwode at Adverum Biotechnologies Inc is $468,103. There are 11 executives at Adverum Biotechnologies Inc getting paid more, with Leone Patterson having the highest compensation of $2,830,320.
What's Thomas Woiwode's mailing address?
Thomas's mailing address filed with the SEC is ONE SANSOME STREET, SUITE 3630, , SAN FRANCISCO, CA, 94104.
Insiders trading at Adverum Biotechnologies Inc
Over the last 9 years, insiders at Adverum Biotechnologies Inc have traded over $1,591,374 worth of Adverum Biotechnologies Inc stock and bought 912,973 units worth $4,153,055 . The most active insiders traders include Patrick Machado, Braden Michael Leonard, and Thomas Woiwode. On average, Adverum Biotechnologies Inc executives and independent directors trade stock every 40 days with the average trade being worth of $200,186. The most recent stock trade was executed by Braden Michael Leonard on 30 July 2024, trading 85,800 units of ADVM stock currently worth $613,470.
What does Adverum Biotechnologies Inc do?
adverum (nasdaq: advm) is a clinical-stage gene therapy company targeting unmet medical needs in serious rare and ocular diseases. we are advancing the development of a robust pipeline of gene therapies that includes product candidates designed to treat rare diseases alpha-1 antitrypsin (a1at) deficiency and hereditary angioedema (hae) as well as wet age-related macular degeneration (wamd). leveraging our next-generation adeno-associated virus (aav)-based directed evolution platform, we generate gene therapies designed to provide durable efficacy by inducing sustained expression of a therapeutic protein.
What does Adverum Biotechnologies Inc's logo look like?
Complete history of Thomas Woiwode stock trades at Adverum Biotechnologies Inc, CRISPR Therapeutics AG, Gritstone Bio Inc, Passage Bio Inc, and Aligos Therapeutics
Adverum Biotechnologies Inc executives and stock owners
Adverum Biotechnologies Inc executives and other stock owners filed with the SEC include:
-
Leone Patterson,
President -
Thomas Leung,
Chief Financial Officer -
Aaron Osborne,
Chief Medical Officer -
Dr. Laurent Fischer,
Pres, CEO, Interim CMO & Director -
Dr. Brigit Riley Ph.D.,
Chief Scientific Officer -
Rekha Hemrajani,
Independent Director -
James Scopa,
Independent Director -
Mark Lupher,
Independent Director -
Patrick Machado,
Independent Chairman of the Board -
Richard Spivey,
Independent Director -
Eric Carter,
Independent Director -
Thomas Woiwode,
Independent Director -
Mehdi Gasmi,
Director -
Myesha Lacy,
Vice President, Investor Relations and Corporate Communications -
Scott Whitcup,
Independent Director -
Peter Soparkar,
Chief legal officer -
Christopher Morrison,
Vice President - Process Development -
Thomas Kochy,
Vice President - Commercial and Program Strategy -
Heikki Jouttijarvi,
Vice President - Manufacturing -
Angela Thedinga,
Chief Technology Officer -
Laurent Fischer,
Chief Executive Officer, Director -
Carla Fiankan,
Sr. VP of Regulatory Affairs -
Nancy E. Pecota,
Principal Accounting Officer -
John W. Rakow J.D.,
Sr. VP, Gen. Counsel & Acting CFO -
Anand Reddi,
VP, Head of Corp. Strategy & External Affairs and Engagement -
Michael Steel,
Sr. VP of Quality -
Dr. Jim Wang Ph.D.,
Sr. VP & Head of Regulatory Affairs -
Dena House,
Sr. VP of HR, Organizational Devel. & Learning -
Kishor Peter Soparkar J.D.,
Chief Operating Officer -
Dr. Rupert D'Souza M.B.A., Ph.D.,
Chief Financial Officer -
Steven Daniel Schwartz,
Director -
Samuel B. Barone,
SVP, Clinical Development -
Athena Countouriotis,
SVP, Chief Medical Officer -
Mitchell H. Finer,
Director -
Carlo Russo,
EVP and Chief Medical Officer -
Jennifer C. Cheng,
General Counsel -
Amber Salzman,
President and CEO -
Paul B Cleveland,
Chief Executive Officer -
Richard Beckman,
Chief Medical Officer -
Szilard Kiss,
-
Soo Hong,
-
Rabia Gurses Ozden,
Chief Medical Officer -
Linda M Rubinstein,
CHIEF FINANCIAL OFFICER -
Dawn Svoronos,
-
Reed Vaughn Tuckson,
-
Rupert D'souza,
Chief Financial Officer -
Julie Clark,
Chief Medical Officer -
Setareh Seyedkazemi,
CHIEF DEVELOPMENT OFFICER -
Braden Michael Leonard,
-
Brigit Riley,
Chief Scientific Officer -
John Rakow,
SVP, Genl Counsel, Acting CFO -
C. David Nicholson,,